On Jan 08, major Wall Street analysts update their ratings for $Denali Therapeutics (DNLI.US)$, with price targets ranging from $24 to $87.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and adjusts the target price from $28 to $24.
BofA Securities analyst Tazeen Ahmad maintains with a buy rating, and adjusts the target price from $34 to $30.
Jefferies analyst Michael Yee maintains with a buy rating, and maintains the target price at $45.
Stifel analyst Paul Matteis maintains with a buy rating, and sets the target price at $37.
BTIG analyst Thomas Shrader maintains with a buy rating, and adjusts the target price from $35 to $32.
Furthermore, according to the comprehensive report, the opinions of $Denali Therapeutics (DNLI.US)$'s main analysts recently are as follows:
The recent disclosure regarding the Phase 2/3 HEALEY trial outcomes, which assessed an agonist of eIF2B in treating amyotrophic lateral sclerosis, led to some disappointment due to the DNL343's lack of success. This is particularly disheartening given the strong pre-clinical indications that suggested a reduction in the aggregation of significant ALS pathology drivers such as TDP-43. It has also been noted that this was among the final legacy projects for Denali, as the company's management is steering its development focus increasingly towards Television (TV) related projects.
Denali Therapeutics is anticipated to evolve into a commercial entity around late 2025 to early 2026, propelled by the potential accelerated FDA endorsement of tividenofusp alfa, an enzyme replacement treatment for Hunter syndrome. Thanks to its ability to penetrate the brain, DNL310 is expected to rapidly secure a substantial portion of the market share, currently held by Elaprase's $700M in annual sales. Additionally, Denali's preclinical 'Peak 2' initiatives aimed at Alzheimer's and Parkinson's diseases are considered promising prospects for the long term.
Here are the latest investment ratings and price targets for $Denali Therapeutics (DNLI.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
